Eric J. Keller, Paul Y. Kwo, Paul R. Helft – 26 October 2013 – The disparity between the demand for and supply of donor livers has continued to grow over the last 2 decades, and this has placed greater weight on the need for efficient and effective liver allocation. Although the use of extended criteria donors has shown great potential, it remains unregulated. A survival benefit–based model was recently proposed to answer calls to increase efficiency and reduce futile transplants.

Sue V. McDiarmid – 24 October 2013

Nicolas Goossens, Francesco Negro – 24 October 2013 – Genotype 3 of the hepatitis C virus (HCV) has been long considered an easy‐to‐treat infection, with higher cure rates (∼70%) than other viral genotypes with the standard combination of pegylated interferon‐α and ribavirin. However, the relative insensitivity of this genotype to most protease inhibitors and the recent unexpected data on decreased effectiveness of sofosbuvir have raised questions on how to achieve universal cure, a goal that seems reasonable for other genotypes.

Nicolas Goossens, Francesco Negro – 24 October 2013 – Genotype 3 of the hepatitis C virus (HCV) has been long considered an easy‐to‐treat infection, with higher cure rates (∼70%) than other viral genotypes with the standard combination of pegylated interferon‐α and ribavirin. However, the relative insensitivity of this genotype to most protease inhibitors and the recent unexpected data on decreased effectiveness of sofosbuvir have raised questions on how to achieve universal cure, a goal that seems reasonable for other genotypes.

Sith Siramolpiwat, Susana Seijo, Rosa Miquel, Annalisa Berzigotti, Angeles Garcia‐Criado, Anna Darnell, Fanny Turon, Virginia Hernandez‐Gea, Jaume Bosch, Juan Carlos Garcia‐Pagán – 23 October 2013 – Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. Data on natural history and prognosis of IPH are limited. We sought to describe the complications and long‐tem outcome of IPH by retrospectively studying 69 biopsy‐proven cases of IPH. Mean duration of follow‐up was 6.7 ± 4.6 years.

Sith Siramolpiwat, Susana Seijo, Rosa Miquel, Annalisa Berzigotti, Angeles Garcia‐Criado, Anna Darnell, Fanny Turon, Virginia Hernandez‐Gea, Jaume Bosch, Juan Carlos Garcia‐Pagán – 23 October 2013 – Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. Data on natural history and prognosis of IPH are limited. We sought to describe the complications and long‐tem outcome of IPH by retrospectively studying 69 biopsy‐proven cases of IPH. Mean duration of follow‐up was 6.7 ± 4.6 years.

Andrew Aronsohn, Nancy Reau, Donald Jensen – 21 October 2013

Bryan C. Fuchs, Yujin Hoshida, Tsutomu Fujii, Lan Wei, Suguru Yamada, Gregory Y. Lauwers, Christopher M. McGinn, Danielle K. DePeralta, Xintong Chen, Toshihiko Kuroda, Michael Lanuti, Anthony D. Schmitt, Supriya Gupta, Andrew Crenshaw, Robert Onofrio, Bradley Taylor, Wendy Winckler, Nabeel Bardeesy, Peter Caravan, Todd R. Golub, Kenneth K. Tanabe – 21 October 2013 – Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer‐related mortality in the United States.

Dechun Feng – 21 October 2013

Andrew Aronsohn, Nancy Reau, Donald Jensen – 21 October 2013